Longeveron Announces 2025 Full Year Financial Results and Provides Business Update Longeveron (NASDAQ: LGVN) reported 2025 results and a business update on March 17, 2026. Revenues fell 50% to $1.2M; net loss widened to $22.7M. The company closed an initial $15M private placement (up to $30M) and expects pivotal Phase 2b ELPIS II HLHS topline results in Q3 2026.Management plans partnering strategies, expects a potential BLA path for HLHS if ELPIS II is successful, and projects cash runway into Q4 2026 after the transaction.

#LGVN #LGVNR Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

www.stocktitan.net/news/LGVN/longeveron-ann...

Longeveron Announces Private Placement of up to $30 Million Longeveron (NASDAQ: LGVN) entered a private placement expected to raise up to $30 million in gross proceeds, with an initial closing of approximately $15 million priced at-the-market under Nasdaq rules.Initial proceeds fund operations into 4Q2026, past anticipated pivotal Phase 2b ELPIS II HLHS topline data in 3Q2026. The financing includes Class A shares and Series A non-voting convertible preferred shares convertible at $0.52, and a contingent second tranche tied to trial milestones and share price.

#LGVN #LGVNR Longeveron Announces Private Placement of up to $30 Million

www.stocktitan.net/news/LGVN/longeveron-ann...

Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy Longeveron (NASDAQ: LGVN) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,496,316 on Dec. 17, 2025 for methods of administering isolated allogeneic mesenchymal stem cells (MSCs) to treat female sexual dysfunction and improve sexual quality of life.The patent provides U.S. rights through 2038 with potential patent term or regulatory exclusivity extensions. The company noted female sexual dysfunction affects up to 46% of women and said the patent expands its aging-focused intellectual property portfolio. Longeveron anticipates pursuing licensing or partnering opportunities for development and commercialization of the therapy.

#LGVN #LGVNR Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy

www.stocktitan.net/news/LGVN/longeveron-gra...

Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum Longeveron (NASDAQ: LGVN) announced that its Chief Science Officer Dr. Joshua Hare and Chief Medical Officer Dr. Nataliya Agafonova will speak at the Global CardioVascular Clinical Trialists (CVCT) Forum in Washington, D.C., December 8-10, 2025.The executives will join multiple panel discussions on cell therapy for heart failure, including delivery routes, cell types (mesenchymal stem cell therapy for dilated cardiomyopathy referencing POSEIDON and PATH AHEAD), and multi‑stakeholder debate on streamlining cell therapy innovation while maintaining evidence standards.

#LGVN #LGVNR Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum

www.stocktitan.net/news/LGVN/longeveron-chi...

Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) Longeveron (NASDAQ: LGVN) announced its submission titled “Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study” was selected for a poster at the 18th Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025), held Dec 1–4, 2025 in San Diego.The poster appears in Poster Session 1 (Section 11: New Therapies and Clinical Trials) with scheduled viewing from Dec 1, 3:00 p.m. PT to Dec 2, 5:30 p.m. PT. The announcement summarizes laromestrocel (Lomecel-B) as a mesenchymal stem cell product proposed to have immunomodulatory and regenerative mechanisms relevant to Alzheimer’s research.

#LGVN #LGVNR Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)

www.stocktitan.net/news/LGVN/longeveron-lar...

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy Longeveron (NASDAQ: LGVN) announced the U.S. Patent and Trademark Office granted U.S. Patent No. 12,465,620 for a method of treating aging-related frailty with inflammaging using human mesenchymal stem cells. The patent provides U.S. rights through 2038, with potential for patent-term or regulatory exclusivity extensions.The company’s lead MSC therapy, laromestrocel, has delivered positive initial results across two clinical trials and prior Phase 1 and 2 studies were designed to show improvements in the six-minute walk test and physical functioning in aging-related frailty patients. Aging-related frailty is described as a multisystem syndrome linked to inflammaging.

#LGVN #LGVNR Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

www.stocktitan.net/news/LGVN/longeveron-gra...

Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update Longeveron (NASDAQ: LGVN) reported Q3 2025 results and a business update on Nov 4, 2025. Key clinical milestones include a fully enrolled pivotal Phase 2b trial ELPIS II for laromestrocel in Hypoplastic Left Heart Syndrome (HLHS) with top-line results expected in Q3 2026 and a potential BLA submission in 2027 if results support efficacy. Laromestrocel has multiple regulatory designations for HLHS and Alzheimer’s disease and an FDA‑accepted IND for pediatric dilated cardiomyopathy with a planned pivotal Phase 2 in 2026, subject to financing.Q3 financials: nine‑month revenue down to $0.8M, net loss $17.3M, and cash of $9.2M as of Sep 30, 2025; cash runway guided into late Q1 2026 with ATM access and prior August financing.

#LGVN #LGVNR Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/LGVN/longeveron-ann...

Longeveron® Announces Key Leadership Updates Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotech company, announced significant leadership changes. Than Powell, previously Chief Business Officer, has been appointed as interim CEO, replacing Wa'el Hashad who is stepping down. Additionally, Dr. Joshua Hare, co-founder and Chief Science Officer, has been appointed as Executive Chairman of the Board.The company's stem cell therapy laromestrocel has shown positive initial outcomes in five clinical trials across three indications. Their pivotal Phase 2b trial for HLHS has achieved full enrollment, with top-line results expected in 2026. The company has expanded its pipeline to include pediatric dilated cardiomyopathy, marking their third program in pivotal clinical trials.

#LGVN #LGVNR Longeveron® Announces Key Leadership Updates

www.stocktitan.net/news/LGVN/longeveron-ann...

Longeveron's Stem Cell Therapy for Fatal Child Heart Condition Reaches Critical Trial Phase Biotech firm completes enrollment in pivotal HLHS pediatric heart trial, eyes 2026 FDA filing. Q2 losses widen to $10M as BLA preparations advance. Learn trial timeline.

#LGVN #LGVNR Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/LGVN/longeveron-ann...

Longeveron Announces Up To $17.5 Million Public Offering Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotech company, has announced a $17.5 million public offering. The offering consists of 5,882,354 shares of Class A common stock (or pre-funded warrants) at $0.85 per share, along with short-term warrants to purchase up to 14,705,885 additional shares.The initial gross proceeds are expected to be $5.0 million, with potential additional proceeds of $12.5 million if all warrants are exercised. The warrants will have an exercise price of $0.85 per share and a 24-month exercise period. The funds will support clinical development of laromestrocel for treating HLHS, Alzheimer's disease, and pediatric DCM, along with regulatory approvals and BLA readiness.

#LGVN #LGVNR Longeveron Announces Up To $17.5 Million Public Offering

www.stocktitan.net/news/LGVN/longeveron-ann...

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease Longeveron (NASDAQ: LGVN) has licensed US Patent 12,168,028 B2 from the University of Miami, acquiring technology for deriving GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells. This breakthrough addresses a significant challenge in cardiovascular stem cell therapy by eliminating the risk of malignant ventricular arrhythmias associated with traditional induced pluripotent stem (iPS) cells.The patented technology selectively produces cells destined to become cardiomyocytes while eliminating cells with electrical automaticity, potentially offering safer therapeutic solutions for various heart conditions. This advancement complements Longeveron's existing pipeline, which includes programs in hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and pediatric dilated cardiomyopathy.

#LGVN #LGVNR Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

www.stocktitan.net/news/LGVN/longeveron-ann...

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS) Longeveron (NASDAQ:LGVN) has completed enrollment for its pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a treatment for Hypoplastic Left Heart Syndrome (HLHS). The trial enrolled 40 pediatric patients across 12 premier institutions, with top-line results expected in Q3 2026.The therapy has received Rare Pediatric Disease, Orphan Drug, and Fast Track designations from the FDA. The ELPIS II trial builds on positive ELPIS I results, which showed 100% transplant-free survival up to five years post-treatment, compared to historical control data showing 20% mortality. If approved, the U.S. market potential is estimated at up to $1 billion.Upon potential FDA approval, Longeveron could receive a Priority Review Voucher, which recently sold for $150-$158 million.

#LGVN #LGVNR Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

www.stocktitan.net/news/LGVN/longeveron-ann...

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient Longeveron (NASDAQ: LGVN) has been selected as a Semi-Finalist and received a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition, a $101 million global initiative aimed at revolutionizing human aging treatment. The company's stem cell therapy laromestorcel has shown positive initial results across 5 clinical trials in 3 indications: Alzheimer's Disease, Aging-related Frailty, and Hypoplastic Left Heart Syndrome (HLHS).The therapy has received five FDA designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations for HLHS, plus RMAT and Fast Track designations for Alzheimer's Disease. As a semifinalist, Longeveron is now eligible to compete for a $1 million milestone prize and a grand prize ranging from $61-81 million. [ "Selected as Top 40 Semifinalist in XPRIZE Healthspan competition, receiving $250,000 Milestone 1 Award", "Positive initial results across 5 clinical trials in 3 indications", "Received 5 significant FDA designations for laromestorcel therapy", "Eligible to compete for additional prizes worth up to $81 million" ]

#LGVN #LGVNR Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

www.stocktitan.net/news/LGVN/longeveron-nam...

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update Longeveron (NASDAQ: LGVN) reported its Q1 2025 financial results and provided updates on its laromestrocel stem cell therapy development. The company's pivotal Phase 2b ELPIS II trial for Hypoplastic Left Heart Syndrome (HLHS) has reached 95% enrollment and is expected to complete in Q2 2025, with potential BLA submission in 2026. Results from the Phase 2a CLEAR MIND trial for Alzheimer's disease were published in Nature Medicine, and the FDA has approved a single, pivotal Phase 2/3 adaptive design trial pathway.Financial highlights include: revenues of $0.4M (down 30% YoY), net loss of $5.0M (up 23% YoY), and cash position of $14.3M, expected to fund operations into Q3 2025. The company plans to seek additional financing to support BLA enabling activities and is pursuing partnership opportunities for its Alzheimer's program.

#LGVN #LGVNR Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/LGVN/longeveron-ann...

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025 Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the Company’s CEO, Wa’el Hashad, issued the

#LGVN #LGVNR Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

www.stocktitan.net/news/LGVN/longeveron-iss...

Breakthrough: FDA Fast-Tracks Novel Cell Therapy for Alzheimer's Treatment - Longeveron Secures Major Regulatory Win First-ever RMAT-designated cell therapy for Alzheimer's advances as FDA supports accelerated approval pathway. Positive trial results show cognitive improvements and safety profile.

#LGVN #LGVNR Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

www.stocktitan.net/news/LGVN/longeveron-ann...

Game-Changing Alzheimer's Treatment: Longeveron's Drug Delivers Cognitive Improvements in Nature Study Groundbreaking Phase 2a trial shows Lomecel-B improves cognitive function in Alzheimer's patients, earning FDA's RMAT designation. Nature Medicine validates significant brain preservation results.

#LGVN #LGVNR Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

www.stocktitan.net/news/LGVN/longeveron-ann...

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update Longeveron reported its full-year 2024 financial results, highlighting a 237% year-over-year increase in total revenue to $2.4 million. The company's pivotal Phase 2b clinical trial (ELPIS II) for Lomecel-B™ in treating Hypoplastic Left Heart Syndrome has achieved over 90% enrollment, with completion expected in Q2 2025.Key financial metrics include a reduced net loss of $16.0 million (down 25% from 2023), with cash and equivalents of $19.2 million as of December 31, 2024. The company anticipates its current funds will support operations into Q4 2025.Notable developments include WHO's approval of 'laromestrocel' as Lomecel-B's non-proprietary name and plans for a potential Biological License Application (BLA) submission in 2026. The company expects an FDA meeting in late Q1 2025 to discuss development paths for Lomecel-B in mild Alzheimer's disease.

#LGVN #LGVNR Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/LGVN/longeveron-ann...

Breakthrough Alzheimer's Treatment Gets Official WHO Recognition - Major Milestone for Rare Disease Therapy Longeveron's Lomecel-B receives WHO naming approval as "laromestrocel", advancing its development for Alzheimer's and rare pediatric heart condition HLHS.

#LGVN #LGVNR Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

www.stocktitan.net/news/LGVN/longeveron-ann...